Another research paper on Ruthenium based PDCsBODIPY-ruthenium(II) polypyridyl complexes: Synthesis, computational, spectroscopic, electrochemical, and singlet oxygen studies Jeremy Erb, Darcy Setter, Jake Swavey, Frederick Willits, Shawn Swavey Department of Chemistry, University of Dayton, 300 College Park, Dayton, OH 45469, United States Received 18 July 2023, Revised 18 September 2023, Accepted 22 October 2023, Available online 29 October 2023.
"...A substantial quantity of research related to developing next generation photosensitizers has resulted in a better understanding of the mechanism of PDT and thus new photosensitizer scaffolds [3], [4], [5]. With their synthetic versatility and exciting photochemical properties Ruthenium(II) polypyridyl complexes occupy a significant proportion of research in the development of new PDT agents [6], [7], [8], [9], [10]. Much of the recent research has focused on extending the aromaticity of the pyridyl ligands to allow for excitation of the Ru-PS within the PDT window (600–850nm) [11], [12], [13], [14], [15], [16]. Currently, however; the only ruthenium-based PDT complex under clinical human trials is TLD1433 which is being evaluated for bladder cancer [17]...."